Table 2.
Decorporation treatment summary.
| Decorporation drug | Dosification | Radionuclide | |
|---|---|---|---|
| Ammonium chloride | Oral | 1–2 g q.i.d., for up to 6 consecutive days | Strontium |
| Ca-DTPA, Zn-DTPA | i.v. | 1 g in 250 ml normal saline or 5% dextrose in water, over 1 h | Americium, plutonium |
| Calcium | oral | Generous doses | Radium, strontium, barium |
| Calcium gluconate | i.v. | 2.5 g administered in 0.5 l D5W over a 4 h period. Daily for 6 consecutive days | Strontium |
| d-Penicillamine | Oral | 250 mg daily between meals and at bedtime. May increase to 4 or 5 g daily in divided doses | Cobalt, indium, palladium |
| Potassium iodide | Oral | 130 mg, as soon as possible, and repeat dose daily until needed | Iodine |
| Potassium phosphate | Oral | 250–500 mg four time daily with full glass of water each time, with meals and at bedtime | Phosphorus |
| Propylthiouracil | Oral | 100 mg three times daily for 8 days | Iodine |
| Prussian blue | Oral | 1 g, three times per day, for up to 3 weeks or longer as required. | Cesium, thallium, rubidium |
| Sodium alginate | Oral | 10 g powder in a 30 cc vial, add water and drink | Strontium |
| Sodium bicarbonate | i.v. | 8.9%, 100 or 200 cc vials. | Uranium |